本帖最后由 老马 于 2012-1-13 21:20 编辑 , X8 W d8 A4 u! m) M( s
) O3 t2 E: H$ ]( l爱必妥和阿瓦斯丁的比较
( a6 @% t7 Y3 t1 W* Z8 o- [- |8 m! F
2 r- N1 E1 U# K( G
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
2 R6 Z- R5 x2 @7 e/ x, O
6 Z/ U3 m2 I. r8 }
& V9 O8 }; K3 C+ Z/ ?- r
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/, @3 Z: V- x: \
==================================================) `5 n; M+ L3 c2 |' a- f C* [
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, E- V, Y" [' I/ w5 ]$ K7 LPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 v, E" [- `2 b5 \Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
$ m. S! P1 I8 z6 B) U3 n7 X8 |8 r
|